Eisai Inc. has appointed Thomas D. Fagan Jr. as VP for the U.S. Alzheimer’s Disease Commercial unit, which will be instrumental in growing the parent firms operations in the US.
BridgeBio announces positive Phase II trial results for achondroplasia, Astellas-Seagen announces promising outcomes from Padcev Plus Keytruda Trial and Kelun-Biotech’s exclusive MSD deal.
The company is readjusting its strategy as it seeks ways to preserve share value. The goal to preserve as much as the $60 million it has in cash and cash equivalents as of the year’s second quarter.
The transaction, Ginkgo’s largest acquisition to date, is expected to close by the first quarter of 2023, subject to regulatory approval and other closing conditions.
Maxvax and Luzhu are raising funds to move their respective research and development programs for recombinant herpes zoster vaccine candidates and new adjuvant products.
Astellas is investing around $70 million, providing lab and co-working spaces to support current and future growth initiatives in the cell and gene therapy space for cancer and rare diseases.
Assembly Biosciences and X4 Pharmaceuticals have announced significant layoffs and reprioritization endeavors to let go of underperforming initiatives.
In what it is calling a strategic decision, Sesen Bio announced Monday that it has paused development activities of Vicineum, its lead asset, in the United States.
Roche had a good week, sharing positive data from Genentech’s study on Vabysmo for age-related macular degeneration and its breast cancer combination therapy, Perjeta.
The agreement with Merck brings $290 million upfront to Orion to access the latter’s investigational candidate, ODM-208, for mCPRC and other related drugs.
Early data from Amgen’s ongoing trial on Lumakras for non-small cell lung cancer hinted at positive results from what could be a transformative combination of drugs versus cancer.
Flagship Pioneering has launched Apriori Bio, which utilizes artificial intelligence to predict virus activity and variant formation, including COVID-19.
Weeks after BridgeBio presented positive biomarker data in Canavan Disease, gene therapy company Myrtelle added its own data to the emerging research space.
